首页 > 最新文献

Hellenic journal of nuclear medicine最新文献

英文 中文
Asymmetric diffuse thyroid uptake on 18F-FDG PET/CT in patient with subacute thyroiditis: Case report and literature review. 亚急性甲状腺炎患者18F-FDG PET/CT不对称弥漫性甲状腺摄取:病例报告和文献复习。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01 Epub Date: 2023-08-04 DOI: 10.1967/s002449912578
Hayato Kaida, Miyuki Wakana, Sawa Yoshida, Yuko Matsukubo, Kazunari Ishii

A 48-year-old man with an intermittent fever of 39.0oC for more than three weeks underwent computed tomography (CT) and blood testing, which revealed no clues. Antibiotics wereadministered, but his condition did not improve. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) showed right-lobe-dominant diffuse thyroid uptake. On technetium-99m (99mTc) pertechnetate scintigraphy, the thyroid gland could not be visualized, and he was diagnosed with subacute thyroiditis (SAT). When asymmetric 18F-FDG diffuse thyroid uptake on PET/CT is observed in a patient with a fever of unknown origin (FUO), SAT may need to be considered.

一名48岁的男子间歇性发烧39.0摄氏度超过三周,他接受了计算机断层扫描(CT)和血液检测,但没有发现任何线索。服用了抗生素,但他的病情没有好转。氟-18氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)显示右叶弥漫性甲状腺摄取占主导地位。在99mTc高锝酸盐闪烁显像中,甲状腺无法显示,他被诊断为亚急性甲状腺炎(SAT)。当在不明原因发热(FUO)患者的PET/CT上观察到不对称18F-FDG弥漫性甲状腺摄取时,可能需要考虑SAT。
{"title":"Asymmetric diffuse thyroid uptake on <sup>18</sup>F-FDG PET/CT in patient with subacute thyroiditis: Case report and literature review.","authors":"Hayato Kaida,&nbsp;Miyuki Wakana,&nbsp;Sawa Yoshida,&nbsp;Yuko Matsukubo,&nbsp;Kazunari Ishii","doi":"10.1967/s002449912578","DOIUrl":"10.1967/s002449912578","url":null,"abstract":"<p><p>A 48-year-old man with an intermittent fever of 39.0<sup>o</sup>C for more than three weeks underwent computed tomography (CT) and blood testing, which revealed no clues. Antibiotics wereadministered, but his condition did not improve. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) showed right-lobe-dominant diffuse thyroid uptake. On technetium-99m (<sup>99m</sup>Tc) pertechnetate scintigraphy, the thyroid gland could not be visualized, and he was diagnosed with subacute thyroiditis (SAT). When asymmetric <sup>18</sup>F-FDG diffuse thyroid uptake on PET/CT is observed in a patient with a fever of unknown origin (FUO), SAT may need to be considered.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 2","pages":"150-154"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10047748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
68Ga-PSMA PET/CT versus 18F-FDG PET/CT for detecting lesions in a case of fumarate hydratase-deficient renal cell carcinoma. 68Ga PSMA PET/CT与18F-FDG PET/CT用于检测富马酸水合酶缺乏型肾细胞癌病例中的病变。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01 Epub Date: 2023-08-04 DOI: 10.1967/s002449912579
Zhibing Qi, Xilan Yao, Minggang Su, Rui Huang

Gallium-68 (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and fluorine-18-fluorodeoxyglucose(18F-FDG) PET/CT were performed for staging in a 51-year-old man with renal cell carcinoma. Compared with 18F-FDG PET/CT, no obvious tracer uptake in right renal mass and less metastatic lesions were found on 68Ga-PSMA PET/CT. Postoperative pathology demonstrated the diagnosis of fumarate hydratase-deficient renal cell carcinoma (FHRCC).

对一名51岁肾细胞癌患者进行了镓-68(68Ga)-前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)和氟-18氟脱氧葡萄糖(18F-FDG)PET/CT分期。与18F-FDG PET/CT相比,68Ga-PSMA PET/CT在右肾肿块中未发现明显的示踪剂摄取,转移灶较少。术后病理证实富马酸水合酶缺乏型肾细胞癌(FHRCC)的诊断。
{"title":"<sup>68</sup>Ga-PSMA PET/CT versus <sup>18</sup>F-FDG PET/CT for detecting lesions in a case of fumarate hydratase-deficient renal cell carcinoma.","authors":"Zhibing Qi,&nbsp;Xilan Yao,&nbsp;Minggang Su,&nbsp;Rui Huang","doi":"10.1967/s002449912579","DOIUrl":"10.1967/s002449912579","url":null,"abstract":"<p><p>Gallium-68 (<sup>68</sup>Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and fluorine-18-fluorodeoxyglucose(<sup>18</sup>F-FDG) PET/CT were performed for staging in a 51-year-old man with renal cell carcinoma. Compared with <sup>18</sup>F-FDG PET/CT, no obvious tracer uptake in right renal mass and less metastatic lesions were found on <sup>68</sup>Ga-PSMA PET/CT. Postoperative pathology demonstrated the diagnosis of fumarate hydratase-deficient renal cell carcinoma (FHRCC).</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 2","pages":"155-156"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10045777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT in evaluation of squamous cell carcinoma. 18F-FDG PET/CT对鳞状细胞癌的评价。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01 Epub Date: 2023-08-04 DOI: 10.1967/s002449912572
Isidora Grozdic Milojevic, Bogomir Milojevic, Dragana Sobic-Saranovic, Nikola Pantic, Jovana Zivanovic, Vera M Artiko

Objective: Squamous cell carcinomas (SCC) are a number of different types of cancer that result from squamous cells. These cells form on the surface of the skin, on the lining of the respiratory and digestive tracts etc. To evaluate SCC and frequencies of their localizations based on the findings of fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT).

Subjects and methods: This study included 343 consecutive patients with SCC who were sent for the 18F-FDG PET/CT. Inclusion criteria were: Pathohistologically verified SCC; absence of malignancy of any other localization, as well as absence of infection; and glycemia ≤11mmol/L.

Results: The pathological findings on 18F-FDG PET/CT were present in 86% of patients. There was statistically significant difference in the finding of 18F-FDG PET/CT in relation to gender (P>0.006). The disease was more often present in women. The most common localizations of disease were: lungs (70%), vagina/cervix (18%), gastrointestinal tract (18%), head and neck (5%). Highest maximum standardized uptake value (SUVmax) levels were seen in the lungs 11.78±8.38, vagina/cervix 11.21±8.10, and head and neck area 6.32±3.96.

Conclusion: Fluorine-18-FDG PET/CT can be informative in evaluation of SCC. Disease is present usually in women, although it is the same pathohistological type of disease, different organs accumulate this radioactive contrast differently.

目的:鳞状细胞癌(SCC)是由鳞状细胞引起的多种不同类型的癌症。这些细胞形成于皮肤表面、呼吸道和消化道内壁等。根据氟-18氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)的结果,评估SCC及其定位频率。受试者和方法:本研究包括343名连续接受18F-FDGPET/CT检查的SCC患者。纳入标准为:病理组织学证实的SCC;没有任何其他定位的恶性肿瘤,以及没有感染;血糖≤11mmol/L。结果:86%的患者有18F-FDG PET/CT的病理表现。18F-FDG PET/CT的发现与性别之间存在统计学上的显著差异(P>0.05)。该疾病更常见于女性。最常见的疾病定位是:肺部(70%)、阴道/宫颈(18%)、胃肠道(18%)和头颈部(5%)。最高标准化摄取值(SUVmax)水平出现在肺11.78±8.38,阴道/宫颈11.21±8.10,头颈部6.32±3.96。结论:氟-18 FDG PET/CT可用于SCC的评估。疾病通常存在于女性身上,尽管它是相同的病理学类型的疾病,但不同的器官积累这种放射性对比是不同的。
{"title":"<sup>18</sup>F-FDG PET/CT in evaluation of squamous cell carcinoma.","authors":"Isidora Grozdic Milojevic,&nbsp;Bogomir Milojevic,&nbsp;Dragana Sobic-Saranovic,&nbsp;Nikola Pantic,&nbsp;Jovana Zivanovic,&nbsp;Vera M Artiko","doi":"10.1967/s002449912572","DOIUrl":"10.1967/s002449912572","url":null,"abstract":"<p><strong>Objective: </strong>Squamous cell carcinomas (SCC) are a number of different types of cancer that result from squamous cells. These cells form on the surface of the skin, on the lining of the respiratory and digestive tracts etc. To evaluate SCC and frequencies of their localizations based on the findings of fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT).</p><p><strong>Subjects and methods: </strong>This study included 343 consecutive patients with SCC who were sent for the <sup>18</sup>F-FDG PET/CT. Inclusion criteria were: Pathohistologically verified SCC; absence of malignancy of any other localization, as well as absence of infection; and glycemia ≤11mmol/L.</p><p><strong>Results: </strong>The pathological findings on <sup>18</sup>F-FDG PET/CT were present in 86% of patients. There was statistically significant difference in the finding of <sup>18</sup>F-FDG PET/CT in relation to gender (P>0.006). The disease was more often present in women. The most common localizations of disease were: lungs (70%), vagina/cervix (18%), gastrointestinal tract (18%), head and neck (5%). Highest maximum standardized uptake value (SUVmax) levels were seen in the lungs 11.78±8.38, vagina/cervix 11.21±8.10, and head and neck area 6.32±3.96.</p><p><strong>Conclusion: </strong>Fluorine-18-FDG PET/CT can be informative in evaluation of SCC. Disease is present usually in women, although it is the same pathohistological type of disease, different organs accumulate this radioactive contrast differently.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 2","pages":"99-107"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10047746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transthyretin (Pro24Ser) variant amyloidosis: A case report of the first patient in Greece. Transthyretin(Pro24Ser)变体淀粉样变性:希腊首例患者的病例报告。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01 DOI: 10.1967/s002449912585
Ioannis Panagiotopoulos, Efstathios Papatheodorou, Aris Anastasakis, Eustathios Kastritis, Polyxeni Gourzi, Zoi Kontogeorgiou, Georgios Koutsis, Georgia Karadima, Maria Koutelou

Objective: Transthyretin cardiac amyloidosis (ATTR-CA) is a rare and potentially fatal disease caused by the accumulation of insoluble transthyretin (TTR) amyloid fibrils in the heart. The symptoms of ATTR-CA are often non-specific, often leading to underdiagnosis. Early diagnosis and treatment have a significant impact on disease progression and mortality.

Case presentation: In this case we report a 73-year-old male presented with dyspnea on exertion. The patient had a medical history of peripheral neuropathy, bilateral carpal tunnel syndrome, spinal fusion, and a family history of coronary artery disease. Upon his presentation at the Cardiology department, cardiac echo study revealed left and right ventricular hypertrophy with pulmonary hypertension, diastolic dysfunction and a restrictive pattern. Because of the high probability of amyloidosis, the patient underwent a technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) bone scintigraphic study, which confirmed the diagnosis of ATTR-CA. Transthyretin gene sequencing analysis revealed the rare p. Pro24Ser pathogenic variant. Final diagnosis was ATTR-CA associated with the proline replaced by serine at position 24 (Pro24Ser) TTR variant, which is rare and only a few cases have been reported worldwide. The patient was treated with tafamidis and inotersen and followed up.

Conclusion: This case highlights the importance of considering amyloidosis as a differential diagnosis for non-specific symptoms and the need for early diagnosis and management of ATTR-CA.

目的:转甲状腺素心脏淀粉样变性(ATTR-CA)是一种罕见且可能致命的疾病,由不溶性转甲状腺素淀粉样原纤维在心脏内积聚引起。ATTR-CA的症状通常是非特异性的,通常导致诊断不足。早期诊断和治疗对疾病进展和死亡率有重大影响。病例介绍:在本病例中,我们报告了一名73岁的男性,在用力时出现呼吸困难。患者有周围神经病变、双侧腕管综合征、脊柱融合病史和冠状动脉疾病家族史。在心脏科的报告中,心脏回声研究显示左心室和右心室肥大伴肺动脉高压、舒张功能障碍和限制性模式。由于淀粉样变性的可能性很高,患者接受了99mTc-3,3-二膦酰基-1,2-丙二羧酸(99mTc-DPD)骨闪烁扫描研究,证实了ATTR-CA的诊断。转甲状腺素基因测序分析揭示了罕见的p.Pro24Ser致病性变体。最终诊断为ATTR-CA与24位丝氨酸取代的脯氨酸(Pro24Ser)TTR变体有关,这是罕见的,全世界只有少数病例报告。患者接受了塔法米迪斯和依诺特生的治疗,并进行了随访。结论:本病例强调了淀粉样变性作为非特异性症状鉴别诊断的重要性,以及早期诊断和治疗ATTR-CA的必要性。
{"title":"Transthyretin (Pro24Ser) variant amyloidosis: A case report of the first patient in Greece.","authors":"Ioannis Panagiotopoulos,&nbsp;Efstathios Papatheodorou,&nbsp;Aris Anastasakis,&nbsp;Eustathios Kastritis,&nbsp;Polyxeni Gourzi,&nbsp;Zoi Kontogeorgiou,&nbsp;Georgios Koutsis,&nbsp;Georgia Karadima,&nbsp;Maria Koutelou","doi":"10.1967/s002449912585","DOIUrl":"10.1967/s002449912585","url":null,"abstract":"<p><strong>Objective: </strong>Transthyretin cardiac amyloidosis (ATTR-CA) is a rare and potentially fatal disease caused by the accumulation of insoluble transthyretin (TTR) amyloid fibrils in the heart. The symptoms of ATTR-CA are often non-specific, often leading to underdiagnosis. Early diagnosis and treatment have a significant impact on disease progression and mortality.</p><p><strong>Case presentation: </strong>In this case we report a 73-year-old male presented with dyspnea on exertion. The patient had a medical history of peripheral neuropathy, bilateral carpal tunnel syndrome, spinal fusion, and a family history of coronary artery disease. Upon his presentation at the Cardiology department, cardiac echo study revealed left and right ventricular hypertrophy with pulmonary hypertension, diastolic dysfunction and a restrictive pattern. Because of the high probability of amyloidosis, the patient underwent a technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid (<sup>99m</sup>Tc-DPD) bone scintigraphic study, which confirmed the diagnosis of ATTR-CA. Transthyretin gene sequencing analysis revealed the rare p. Pro24Ser pathogenic variant. Final diagnosis was ATTR-CA associated with the proline replaced by serine at position 24 (Pro24Ser) TTR variant, which is rare and only a few cases have been reported worldwide. The patient was treated with tafamidis and inotersen and followed up.</p><p><strong>Conclusion: </strong>This case highlights the importance of considering amyloidosis as a differential diagnosis for non-specific symptoms and the need for early diagnosis and management of ATTR-CA.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 2","pages":"145-149"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10408333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT in monoclonal plasma cell disorders. 18F-FDG PET/CT在单克隆浆细胞疾病中的应用。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01
Anna Paschali

Plasma cell disorders are a heterogeneous group caused by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow. Multiple Myeloma (MM) is the most serious and prevalent plasma cell dyscrasia, with a median age of onset of 60 years.MM displays significant genetic, biological and clinical heterogeneity with subsequent imaging heterogeneity, evident in contemporary imaging modalities (PET/CT and MRI). Evidence suggests that MM is always preceded by precursor stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.

浆细胞疾病是由骨髓中淋巴浆细胞的单克隆增殖引起的一组异质性疾病。多发性骨髓瘤(MM)是最严重和最普遍的浆细胞异常,中位发病年龄为60岁。MM表现出显著的遗传、生物学和临床异质性,随后的成像异质性在当代成像模式(PET/CT和MRI)中很明显。有证据表明,MM之前总是有意义不明的单克隆gammopathy(MGUS)和闷烧性多发性骨髓瘤的前体阶段。
{"title":"<sup>18</sup>F-FDG PET/CT in monoclonal plasma cell disorders.","authors":"Anna Paschali","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Plasma cell disorders are a heterogeneous group caused by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow. Multiple Myeloma (MM) is the most serious and prevalent plasma cell dyscrasia, with a median age of onset of 60 years.MM displays significant genetic, biological and clinical heterogeneity with subsequent imaging heterogeneity, evident in contemporary imaging modalities (PET/CT and MRI). Evidence suggests that MM is always preceded by precursor stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"38-41"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radioiodine refractory differentiated thyroid cancer. 放射性碘难治性分化甲状腺癌。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01
Maria Boudina

Differentiated thyroid cancer is composed of papillary (85%), follicular (13%) with their subtypes and anaplastic (<2%) thyroid cancer, derived from follicular dedifferentiation. In the majority of cases (85%), treatment is succeeded with thyroxine suppression and radioiodine ablation. However, there is a small percentage of patients presenting with local recurrence or metastases during follow up. In such cases, reoperation and radioiodine treatment are the treatments of choice. 10% of the aforementioned patients appear resistance to radioiodine treatment and they are considered refractory to iodide. As refractory to radioiodine is defined a patient who fulfills one of the following criteria: 1. Negative RAI Uptake 2. RAI uptake in some but not all metastases 3. Disease progression 6-12 months after Radioiodine ablation 4. Disease progression after radioiodine treatment more of than 600mCi.

分化型甲状腺癌由乳头状癌(85%)、滤泡癌(13%)及其亚型和间变性癌(
{"title":"Radioiodine refractory differentiated thyroid cancer.","authors":"Maria Boudina","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Differentiated thyroid cancer is composed of papillary (85%), follicular (13%) with their subtypes and anaplastic (<2%) thyroid cancer, derived from follicular dedifferentiation. In the majority of cases (85%), treatment is succeeded with thyroxine suppression and radioiodine ablation. However, there is a small percentage of patients presenting with local recurrence or metastases during follow up. In such cases, reoperation and radioiodine treatment are the treatments of choice. 10% of the aforementioned patients appear resistance to radioiodine treatment and they are considered refractory to iodide. As refractory to radioiodine is defined a patient who fulfills one of the following criteria: 1. Negative RAI Uptake 2. RAI uptake in some but not all metastases 3. Disease progression 6-12 months after Radioiodine ablation 4. Disease progression after radioiodine treatment more of than 600mCi.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"65-68"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound investigation and management of the thyroid nodule.Tirads classification.Patient's follow-up after thyroidectomy. 甲状腺结节的超声检查和治疗。Tirads分类。甲状腺切除术后患者的随访。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01
Evangelos G Destanis

Thyroid's ultrasound examination is the first and main imaging modality for the morphological investigation of the gland following clinical examination. It depicts both the number and texture of both palpable and non-palpable nodules.

甲状腺超声检查是临床检查后进行甲状腺形态学研究的第一种也是主要的成像方式。它描绘了可触及和不可触及结节的数量和质地。
{"title":"Ultrasound investigation and management of the thyroid nodule.Tirads classification.Patient's follow-up after thyroidectomy.","authors":"Evangelos G Destanis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thyroid's ultrasound examination is the first and main imaging modality for the morphological investigation of the gland following clinical examination. It depicts both the number and texture of both palpable and non-palpable nodules.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"69-82"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 核医学在胃肠胰神经内分泌肿瘤(GEP-NETs)诊断和治疗中的当前作用。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01
Alexandros Georgakopoulos

Neuroendocrine tumors (NETs), are heterogenic neoplasms that arise from the disseminated endocrine cell system, primarily from gastroenteropancreatic (GEP) organs. Nuclear Medicine has a central role in both diagnosis and treatment of GEP-NETs. Somatostatin receptor scintigraphy (SRS) is still performed with SPECT/CT in case that PET/CT is not available but numerous studies have demonstrated the superior diagnostic accuracy of the latter for GEP-NETs. 68Ga -Dota peptide PET/CT (SSA-PET/CT) has high sensitivity, specificity and accuracy (86%-100%) and is recommended for the staging as also for the restaging of GEP-NETs.

神经内分泌肿瘤(NETs)是一种起源于播散性内分泌细胞系统的异质性肿瘤,主要来自胃肠胰(GEP)器官。核医学在GEP NETs的诊断和治疗中发挥着核心作用。在PET/CT不可用的情况下,生长抑素受体闪烁扫描(SRS)仍然使用SPECT/CT进行,但许多研究已经证明后者对GEP-NETs具有优越的诊断准确性。68Ga-Dota肽PET/CT(SSA-PET/CT)具有高灵敏度、特异性和准确性(86%-100%),建议用于GEP-NETs的分期和再分期。
{"title":"Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).","authors":"Alexandros Georgakopoulos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neuroendocrine tumors (NETs), are heterogenic neoplasms that arise from the disseminated endocrine cell system, primarily from gastroenteropancreatic (GEP) organs. Nuclear Medicine has a central role in both diagnosis and treatment of GEP-NETs. Somatostatin receptor scintigraphy (SRS) is still performed with SPECT/CT in case that PET/CT is not available but numerous studies have demonstrated the superior diagnostic accuracy of the latter for GEP-NETs. <sup>68</sup>Ga -Dota peptide PET/CT (SSA-PET/CT) has high sensitivity, specificity and accuracy (86%-100%) and is recommended for the staging as also for the restaging of GEP-NETs.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"49-51"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10135775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in breast cancer treatment. 癌症治疗的最新进展。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01
Sophia Levva

Breast cancer treatment is determined by the molecular subtype both in the early stage and the advanced disease. While there is clear benefit from adjuvant systemic treatment for patients with early-stage triple negative and HER2 positive breast cancer, it was unclear in the past which patient with luminal breast cancer needs adjuvant chemotherapy. As a result, we used to overtreat or undertreat patients. In the era of personalized treatment, genomic panels have become as or more important than the anatomic extent of disease to define prognosis in luminal breast cancer. Several gene expression assays are available for consideration of adjuvant systemic therapy categorizing patients according to genomic risk for recurrence (e.g., Oncotype, Mammaprint, etc). Except for the high and low risk signature, more recently Mammaprint announced that patients with ultra-low risk signature have excellent prognosis, distinctive from low risk with 8-year BCSS above 99%, regardless of age, clinical risk or treatment received. Very few patients developed distant metastasis, allowing physicians to de-escalate treatment plans.

癌症治疗是由早期和晚期疾病的分子亚型决定的。虽然辅助全身治疗对早期三阴性和HER2阳性的癌症患者有明显的益处,但过去尚不清楚哪一位管腔型癌症患者需要辅助化疗。因此,我们过去常常过度治疗或治疗不足的患者。在个性化治疗的时代,基因组小组已经变得比疾病的解剖范围更重要,以确定腔型乳腺癌症的预后。有几种基因表达测定可用于考虑辅助系统治疗,根据复发的基因组风险对患者进行分类(例如,Onctype、Mammaprint等)。除了高风险和低风险特征外,Mammaprint最近宣布,具有超低风险特征的患者预后良好,与8年BCSS高于99%的低风险患者不同,无论年龄、临床风险或接受的治疗如何。很少有患者出现远处转移,这使得医生可以降低治疗计划。
{"title":"Recent advances in breast cancer treatment.","authors":"Sophia Levva","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast cancer treatment is determined by the molecular subtype both in the early stage and the advanced disease. While there is clear benefit from adjuvant systemic treatment for patients with early-stage triple negative and HER2 positive breast cancer, it was unclear in the past which patient with luminal breast cancer needs adjuvant chemotherapy. As a result, we used to overtreat or undertreat patients. In the era of personalized treatment, genomic panels have become as or more important than the anatomic extent of disease to define prognosis in luminal breast cancer. Several gene expression assays are available for consideration of adjuvant systemic therapy categorizing patients according to genomic risk for recurrence (e.g., Oncotype, Mammaprint, etc). Except for the high and low risk signature, more recently Mammaprint announced that patients with ultra-low risk signature have excellent prognosis, distinctive from low risk with 8-year BCSS above 99%, regardless of age, clinical risk or treatment received. Very few patients developed distant metastasis, allowing physicians to de-escalate treatment plans.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 Suppl ","pages":"83-84"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
99mTc-pertechnetate thyroid static scintigraphy unexpectedly revealed ectopic gastric mucosa of upper esophagus. 99mTc-高锝酸甲状腺静态闪烁显像意外地显示了食管上部异位的胃粘膜。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-05-01 Epub Date: 2023-08-04 DOI: 10.1967/s002449912580
Yixuan Ren, Guohao Jiang, Yang Meng, Jianglin Chen, Jiangyan Liu

Technetium-99m (99mTc)-pertechnetate can be taken up by both gastric mucosa and thyroid tissue. Ectopic gastric mucosa of upper esophagus found in thyroid scintigraphy is rare. We reported a 31-year-old woman who underwent 99mTc-pertechnetate thyroid static scintigraphy for abnormal ultrasound findings. A focal uptake lesion was found in her upper chest. Single photon emission computed tomography/computed tomography (SPECT/CT) imaging showed increased uptake in multiple sites of the upper esophagus without significant thickening. Eventually, gastroscopic findings revealed multiple ectopic gastric mucosa of upper esophagus.

99mTc高锝酸盐可被胃黏膜和甲状腺组织吸收。甲状腺闪烁扫描发现食管上段异位胃黏膜是罕见的。我们报告了一位31岁的女性,她接受了99mTc-高锝酸盐甲状腺静态闪烁扫描,以发现异常的超声检查结果。在她的上胸部发现了局灶性摄取损伤。单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)成像显示,食管上部多个部位的摄取增加,但没有明显增厚。最终,胃镜检查结果显示食管上部有多处异位胃粘膜。
{"title":"<sup>99m</sup>Tc-pertechnetate thyroid static scintigraphy unexpectedly revealed ectopic gastric mucosa of upper esophagus.","authors":"Yixuan Ren,&nbsp;Guohao Jiang,&nbsp;Yang Meng,&nbsp;Jianglin Chen,&nbsp;Jiangyan Liu","doi":"10.1967/s002449912580","DOIUrl":"10.1967/s002449912580","url":null,"abstract":"<p><p>Technetium-99m (<sup>99m</sup>Tc)-pertechnetate can be taken up by both gastric mucosa and thyroid tissue. Ectopic gastric mucosa of upper esophagus found in thyroid scintigraphy is rare. We reported a 31-year-old woman who underwent <sup>99m</sup>Tc-pertechnetate thyroid static scintigraphy for abnormal ultrasound findings. A focal uptake lesion was found in her upper chest. Single photon emission computed tomography/computed tomography (SPECT/CT) imaging showed increased uptake in multiple sites of the upper esophagus without significant thickening. Eventually, gastroscopic findings revealed multiple ectopic gastric mucosa of upper esophagus.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 2","pages":"157-159"},"PeriodicalIF":1.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10102511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hellenic journal of nuclear medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1